Home Virology Coronavirus Mammoth Pursues Coronavirus Partnership as It Grows CRISPR Ambitions

MammothBio2-121 — Mammoth Biosciences has raised $45 million in an oversubscribed Series B financing with the goal of expanding beyond CRISPR-based disease detection—including a collaboration targeting 2019-nCoV coronavirus—toward offerings that apply the company’s platform to gene editing and next generation therapeutics. [Mammoth Biosciences]

Mammoth Pursues Coronavirus Partnership as It Grows CRISPR Ambitions

Fresh off $45-million Series B round, the CRISPR diagnostics developer expands beyond disease detection into gene editing partnerships and next-gen therapeutics

By Alex Philippidis

January 30, 2020

Mammoth Biosciences has raised $45 million in an oversubscribed Series B financing with the goal of expanding beyond CRISPR-based disease detection—including a collaboration targeting 2019-nCoV coronavirus—toward offerings that apply the company’s platform to gene editing and next generation therapeutics. [Mammoth Biosciences]

Mammoth Biosciences has raised $45 million in an oversubscribed Series B financing with the goal of expanding beyond CRISPR-based disease detection—including a collaboration targeting 2019-nCoV coronavirus—towards offerings that apply the company’s platform to gene editing and next-generation therapeutics . . .